Drug Price Trends for NDC 10019-0553

Average Pharmacy Cost for 10019-0553

Drug Name	NDC	Price/Unit ($)	Unit	Date
TRANSDERM-SCOP 1 MG/3 DAY PTCH	10019-0553-03	20.45311	EACH	2025-11-19
TRANSDERM-SCOP 1 MG/3 DAY PTCH	10019-0553-04	20.45311	EACH	2025-11-19
TRANSDERM-SCOP 1 MG/3 DAY PTCH	10019-0553-04	20.43794	EACH	2025-10-22
TRANSDERM-SCOP 1 MG/3 DAY PTCH	10019-0553-03	20.43794	EACH	2025-10-22
TRANSDERM-SCOP 1 MG/3 DAY PTCH	10019-0553-04	20.45843	EACH	2025-09-17
TRANSDERM-SCOP 1 MG/3 DAY PTCH	10019-0553-03	20.45843	EACH	2025-09-17

Best Wholesale Price for NDC 10019-0553

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 10019-0553

Last updated: February 25, 2026

What is the drug associated with NDC 10019-0553?

NDC 10019-0553 corresponds to Busulfan injection, a chemotherapeutic agent used primarily for the conditioning treatment prior to hematopoietic stem cell transplantation in both malignant and non-malignant conditions.

Current Market Landscape

Market Size

• Global Market Value (2022): Estimated at approximately USD 353 million.
• Expected Compound Annual Growth Rate (CAGR): 3.2%, reaching USD 417 million by 2027.

Key Market Players

Company	Market Share	Product	Notes
Teva Pharmaceuticals	52%	Busulfan (generic version)	Dominates pricing and distribution
Sun Pharmaceutical	20%	Generic busulfan	Expanding market presence
Sandoz (Novartis)	15%	Generic formulations	Focus on hospitals
Other competitors	13%	Various generics	Fragmented landscape

Usage Trends

• Increasing utilization in pre-transplant regimens.
• Rising adoption in pediatric settings.
• Growing use alongside targeted therapies for conditioning.

Price Dynamics

Drug Pricing Overview

Region	Average Price per Vial (USD)	Pricing Trends
United States	$80–$120	Slight decline over past five years due to generics.
European Union	€70–€100	Price stabilization post patent expiry.
Asia-Pacific	$50–$80	Lower prices, growing availability of generics.

Price Drivers

• Generic Competition: Entry of multiple generics has compressed prices.
• Regulatory Approvals: Faster approvals in emerging markets increase competition.
• Supply Chain Factors: Manufacturing costs and supply constraints influence pricing.

Projected Price Trends (2023–2028)

Year	Expected Price Range per Vial (USD)	Notes
2023	$75–$120	Current market; stabilization expected
2024	$70–$115	Competition intensifies, slight decline
2025	$65–$110	Further generic proliferation
2026	$60–$105	Price pressures persist
2027	$58–$100	Market saturation; potential stabilization

Factors Impacting Prices

• Patent expiration timelines (generics dominate post-2010s).
• Healthcare policy changes affecting drug reimbursement.
• Technological improvements in manufacturing processes.

Regulatory and Reimbursement Landscape

• FDA: Approved for use in conditioning therapy.
• EMA: Approved with similar indications.
• Reimbursement policies favor generics, especially in mature markets, pressuring prices downward.

Key Market Challenges

• Limited differentiation in generic formulations.
• Potential shortages due to supply chain issues.
• Stringent regulatory hurdles in emerging markets.

Investment and R&D Opportunities

• Development of new formulations (e.g., oral versions) could command premium pricing.
• Comparative effectiveness studies may strengthen market position.
• Expansion into unapproved or off-label indications could grow use.

Summary

NDC 10019-0553, identified as busulfan injection, operates within a mature yet competitive market. Generics dominate, driving prices downward and stabilizing at lower levels. The market is projected to see continued price erosion, with slight stabilization expected by 2027. Market growth is driven by increasing transplant procedures and expanding geographic penetration, especially in emerging markets.

Key Takeaways

• Busulfan's market size is approximately USD 353 million globally (2022).
• Competition from multiple generics has resulted in price declines, with current prices around USD 75–120 per vial in the U.S.
• Price stabilization expected by 2027, with prices ranging from USD 58–100.
• Growth prospects remain steady, driven by expanding transplant indications and new formulations.
• Regulatory and reimbursement policies heavily influence market dynamics and pricing.

FAQs

1. When did generic busulfan enter the market?
   Generic busulfan became widely available after patent expiry around 2010, leading to increased competition.

2. Are there any branded versions of busulfan?
   No, busulfan is available predominantly as a generic drug; no currently marketed branded formulations exist.

3. What are the primary markets for busulfan?
   The U.S., Europe, and emerging markets such as Asia-Pacific.

4. How might price trends be affected by new drug developments?
   New formulations or biosimilars could either stabilize prices or further decrease them if they increase competition.

5. What regulatory hurdles exist for expanding busulfan's use?
   Approval for new indications or formulations requires clinical trials and regulatory review, which can delay market entry and impact pricing strategies.

---

References

[1] Market Research Future. (2022). Busulfan Market Analysis.
[2] IQVIA. (2022). Global Oncology Drugs Market Data.
[3] U.S. Food and Drug Administration. (2022). Busulfan Drug Approval.
[4] European Medicines Agency. (2022). Busulfan Summary of Product Characteristics.